The Wegovy 1.5ml pen: how volume, dose and the right decision connect

Why the 1.5ml figure appears, and what it does not tell you

When you look up Wegovy pen specifications, the 1.5ml figure comes from the cartridge inside the device: Novo Nordisk fills each pen with 1.5ml of semaglutide solution. That number is a manufacturing constant, not a dose. What changes across the pen range is the concentration of semaglutide dissolved in that liquid. A 0.25mg starter pen and a 2.4mg maintenance pen both contain 1.5ml, the drug is simply more concentrated in the higher-strength version.

This matters practically because some people try to estimate how much medication remains in a pen, or wonder whether a partially used pen can be saved. It cannot. Each pen delivers one pre-set weekly dose and then locks. There is no window to inspect or measure remaining fluid, and the mechanism is not designed to be reset. The Wegovy pen overview covers how the device mechanism works in full, including what the locked state looks and feels like.

If you have ever wondered how the 1.5ml relates to the number of injections per pen, the answer is straightforward: one pen, one injection, one week's dose. The single-pen dispensing question comes up often at consultation, and it is worth clarifying before your first delivery arrives.

The practical decision the volume figure prompts: checking your pen before you inject

Because the 1.5ml is a sealed, pre-filled quantity, the relevant pre-injection check is not about measuring volume, it is about confirming the solution looks right. Before each injection, hold the pen up to the light and look through the inspection window if your pen model has one. The solution should be clear to slightly yellow and free from particles or cloudiness. If it looks discoloured, cloudy or contains visible flecks, do not inject: contact your prescriber or pharmacist the same day.

This check takes under a minute and is the single most useful habit you can build around pen use. It is also worth confirming the pen has been stored correctly: Wegovy pens should be kept refrigerated at 2–8°C until needed. For exact storage windows and what to do if a pen has been left out, the NHS semaglutide page is the clearest patient-level reference.

On the question of needle attachment: Wegovy pens require a new needle for each injection. The needle is not pre-attached in the box. Attaching a fresh one before every use (and removing it immediately afterwards) is part of the standard injection routine your prescriber or the patient information leaflet will walk you through. Used needles and the pen itself go into a sharps container after use; never into household recycling or a bin.

How the 1.5ml pen fits into the wider Wegovy dose journey

Wegovy's licensed titration path begins at 0.25mg weekly and climbs in stages (typically every four weeks) up to the 2.4mg maintenance dose, with the MHRA having now approved a higher 7.2mg option for eligible adults. Each step along that path is delivered via the same 1.5ml pen format; what you receive changes by strength, not by pen size. Your prescriber reviews your progress before authorising any dose increase, and that clinical re-check is not optional: it is part of how the treatment stays safe.

If you are thinking about what the different strengths look like side by side, the guide to Wegovy pen volumes by strength sets out how dose and concentration relate across the full range. For those specifically moving between the 1ml and the 1.5ml dose-step presentations, the 1ml pen page gives the relevant context. And if cost is a factor in planning your treatment, the Wegovy cost page explains how private pricing is structured across the dose steps.

Clinical trial data supports the efficacy of the titrated approach: the STEP 1 trial, published in the New England Journal of Medicine, reported an average body-weight reduction of around 15% over 68 weeks in adults using semaglutide 2.4mg weekly alongside lifestyle changes. Those results were achieved through the structured titration the pen design supports, not by jumping straight to the highest dose.

When to get medical help, and how to flag a concern

Semaglutide's most common side effects are gastrointestinal: nausea, loose stools, constipation, indigestion and burping are all reported, especially after starting or stepping up. Most people find these settle within a couple of weeks. Drink plenty of water, eat slowly, and keep portions modest, your appetite will likely be lower than usual.

Certain symptoms need prompt medical attention. Severe, persistent stomach pain that radiates towards the back, with or without vomiting, should be assessed urgently: this pattern can indicate pancreatitis, and the MHRA has specifically highlighted it in guidance for people using GLP-1 medicines. Signs of an allergic reaction, including swelling of the face or throat, also need emergency care. Gallbladder symptoms (sharp pain in the upper right abdomen) are another reason to call your GP or 111 rather than waiting. If you notice any reaction at all that concerns you, the nu me FAQs point to where you can reach the aftercare team.

Suspected side effects can be reported directly to the MHRA through the Yellow Card scheme, this applies to both side effects from genuine medicine and any concerns about a product that may not be genuine. If you are unsure whether your pen looks or feels as expected, report it rather than guessing.